In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

The Northeast Microelectronics Coalition Hub announced on Wednesday that it had been awarded $37.8 million in federal ...

Opens in a new tab or window Glucagon-like peptide 1 (GLP-1) receptor agonists like semaglutide (Ozempic, Wegovy ... how they will pay for them and stay in business. The Centers for Medicare & ...

Ozempic is not approved for use in weight loss, however, many people have been taking the drug for this purpose. Semaglutide was approved for weight loss purposes under another name—Wegovy—which has a ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

As Novo Nordisk rakes in billions, Sen. Bernie Sanders and public health advocates demand answers on why U.S. patients are charged sky-high prices for life-saving drugs like Ozempic while generics ...

This news of Ozempic price cuts comes on the heels, or tablet, of Novo Nordisk developing a weight loss pill that mirrors the ...

Some drugmakers' submission of multiple "use codes" to expand patent claims appears to be delaying the arrival of lower-cost ...

Also, Sen. Bernie Sanders spoke up again about Ozempic's manufacturer Novo Nordisk, alleging that it can make and sell its weight loss drug for under $100 a month. Meanwhile, CNN notes that GLP-1 ...

The drugmaker fell 1.4% on pricing fears for its blockbuster Ozempic offering. Bloomberg reported the diabetes drug is likely to be a treatment targetted for US price cuts under the Medicare scheme.

Shares of Novo Nordisk (NYSE:NVO) fell on Wednesday after Bloomberg reported that Ozempic, Novo Nordisk’s diabetes drug, is ...